Collaborative Innovation Award, Clinical and Translational Science Award (CTSA) Program (U01)
Deadline: March 8, 2018; July 11, 2018
Amount: Up to $1,000,000 direct costs annual budget (clinical projects)
Up to $500,000 direct costs annual budget (non-clinical projects);
Maximum project period is 5 years
This FOA aims to support applications for innovative collaborative investigations (involving three or more CTSA sites) into improvements of the methods of translational research, at any step in the translational spectrum (T1-T4). It is anticipated that the combined effort of three or more CTSA hubs in flexible networks will substantially enhance the effectiveness of the CTSA consortium to address high priority translational research questions. This FOA therefore aims to support innovative and collaborative experimental translational research projects carried out in the CTSA consortium that have the following characteristics:
First, such projects should develop a new technology, method, or approach that addresses a general roadblock in science and/or operations that limits the efficiency and effectiveness of translation. As defined at NCATS, translation is the process of turning observations in the laboratory, clinic, and community into interventions that improve the health of individuals and the public - from diagnostics and therapeutics to medical procedures and behavioral changes. This FOA also supports innovative approaches to training or community/patient engagement that are focused on improving translation.
Second, such projects should demonstrate in one or more use cases whether the tool, method, or approach is effective in accelerating translation, utilizing clear and meaningful metrics and outcomes, when implemented across multiple CTSA hubs.
Third, such projects should advance collaboration, building on existing strengths and resources of individual CTSA hubs. Investigators who are not affiliated with a CTSA hub, but wish to bring an innovative project to the CTSA consortium, can participate in collaboration with a CTSA investigator. Whenever possible, projects should include partnerships between CTSA hubs and external stakeholders such as industry or patient organizations. This is desirable so that the partners can mutually leverage resources, assure meaningful intervention approaches, and increase the likelihood of successful hand-off to the private sector when appropriate.
Fourth, what constitutes success of the proposed project can be defined and measured.
- Clinical trial optional
- Applicants are encouraged to contact the NCATS Scientific/Research contact to discuss programmatic priority. (As of April 25, 2016, X02 pre-applications are no longer recommended or accepted)